These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29201779)

  • 1. HBV Treatment in Turkey: The Value of Hepatitis B Surface Antigen Quantification of Chronic Hepatitis B Patients in the Long-term Follow-up-A Single-center Study.
    Ozkan H
    Euroasian J Hepatogastroenterol; 2017; 7(1):82-83. PubMed ID: 29201779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of Chronic Hepatitis B in Turkey.
    Özkan H
    Euroasian J Hepatogastroenterol; 2018; 8(1):73-74. PubMed ID: 29963468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase.
    Chen L; Shi J; Lu Z; Ye Y; Zhou X; Tan Y
    Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):310-316. PubMed ID: 30528063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?
    Sali S; Sharafi H; Alavian SH; Alavian SM; Etesam F; Salimi S; Merza MA; Keshvari M
    Diagn Microbiol Infect Dis; 2015 Jun; 82(2):114-9. PubMed ID: 25863529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Chronic Hepatitis B using HBsAg-based Vaccine Formulations: From Preventive Commercial Vaccines to Therapeutic Approach Julio Cesar Aguilar.
    Cesar Aguilar J; Y L
    Euroasian J Hepatogastroenterol; 2014; 4(2):92-97. PubMed ID: 29699355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiviral nucleotide-induced dynamic change of HBV DNA and HBsAg and significance of quarterly and annual quantitative measurements over 5-year follow-up of chronic hepatitis B patients].
    Xi HL; Li MR; Bao Y; Yu M; Qin XQ; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):821-4. PubMed ID: 24331690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection.
    Tan Z; Li M; Kuang X; Tang Y; Fan Y; Deng G; Wang Y; He D
    J Clin Virol; 2014 Apr; 59(4):228-34. PubMed ID: 24529415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA.
    Liu YY; Liang XS
    World J Hepatol; 2018 Sep; 10(9):603-611. PubMed ID: 30310538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.
    Chung KH; Kim W; Kim BG; Lee HY; Jin E; Cho Y; Seo JY; Kim HY; Jung YJ; Kim JW; Jeong JB; Lee KL
    Gut Liver; 2015 Sep; 9(5):657-64. PubMed ID: 25717049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
    Sonneveld MJ; Zoutendijk R; Janssen HL
    J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.
    Seto WK; Wong DK; Fung J; Huang FY; Liu KS; Lai CL; Yuen MF
    Clin Microbiol Infect; 2014 Nov; 20(11):1173-80. PubMed ID: 24975365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
    Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.